评估EFSUMB CEUS胰腺应用指南(2017版)对455例实性胰腺肿块的诊断效能:一项回顾性单中心分析
本回顾性单中心研究纳入2017年1月至2020年12月455个实性胰腺病灶,评估EFSUMB CEUS胰腺应用指南(2017版)以低增强诊断胰腺导管腺癌(PDAC)的效能;在补充等增强和极快/快廓清标准后重新分类,诊断准确率由69.5%升至95.8%,敏感度由65.4%升至99.2%,ROC由0.747升至0.916。
要点
- EFSUMB指南以低增强为唯一PDAC诊断标准时,敏感度65.4%、特异度84%、准确率69.5%。
- 补充等增强和极快/快廓清标准后,敏感度升至99.2%、准确率升至95.8%、ROC升至0.916。
- 特异度在重新分类前后均为84%,提示补充标准主要提高敏感度和阴性预测值。
核心结论
- EFSUMB胰腺病灶指南通过CEUS低增强可有效识别PDAC,但补充等增强和极快/快廓清模式后重新分类可进一步提高诊断效能。
研究设计与样本
- 回顾性单中心研究,纳入2017年1月至2020年12月450例患者共455个实性胰腺病灶,中位年龄58.37岁,男性250例;参考标准为组织学评估或复合影像与临床随访结果。
关键影像表现/征象
- PDAC在CEUS上表现为低增强,等增强和极快/快廓清模式被作为补充诊断标准。
- CEUS的实时动态衰减能力可反映PDAC的血供模式。
诊断标准与关键数值
- EFSUMB指南标准:PDAC表现为所有期相低增强,据此诊断PDAC的ACC 69.5%、SEN 65.4%、SPE 84%、PPV 93.5%、NPV 40.6%、ROC 0.747。
- 补充标准:加入等增强和极快/快廓清模式后重新分类,诊断PDAC的ACC 95.8%、SEN 99.2%、SPE 84%、PPV 95.7%、NPV 96.6%、ROC 0.916。
临床应用与阅片要点
- 阅片时可依据EFSUMB指南以低增强识别PDAC,并注意等增强和极快/快廓清模式作为补充诊断线索。
- CEUS实时动态衰减能力有助于评估PDAC血供模式,为诊断提供额外信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To explore the diagnostic performance of EFSUMB CEUS Pancreatic Applications guidelines (version 2017) before and after the addition of iso-enhancement and very fast/fast washout as supplementary diagnostic criteria for PDAC.
METHODS: In this retrospective study, patients diagnosed with solid pancreatic lesions from January 2017 to December 2020 were evaluated. Pancreatic ductal adenocarcinoma (PDAC) is reported to show hypo-enhancement in all phases according to the EFSUMB guidelines. First, based on this definition, all lesions were categorized as PDAC and non-PDAC. Then, iso-enhancement and very fast/fast washout were added as supplementary diagnostic criteria, and all lesions were recategorized. The diagnostic performance was assessed in terms of the accuracy (ACC), sensitivity (SEN), specificity (SPE), positive predictive value (PPV), and negative predictive value (NPV). The reference standard consisted of histologic evaluation or composite imaging and clinical follow-up findings.
RESULTS: A total of 455 nodules in 450 patients (median age, 58.37 years; 250 men) were included. The diagnostic performance using the EFSUMB CEUS guidelines for PDAC had an ACC of 69.5%, SEN of 65.4%, SPE of 84%, PPV of 93.5%, NPV of 40.6%, and ROC of 0.747. After recategorization according to the supplementary diagnostic criteria, the diagnostic performance for PDAC had an ACC of 95.8%, SEN of 99.2%, SPE of 84%, PPV of 95.7%, NPV of 96.6%, and ROC of 0.916.
CONCLUSION: The EFSUMB guidelines and recommendations for pancreatic lesions can effectively identify PDAC via hypo-enhancement on CEUS. However, the diagnostic performance may be further improved by the reclassification of PDAC lesions after adding iso-enhancement and very fast/fast washout mode.
KEY POINTS: • In the EFSUMB guidelines, the only diagnostic criterion for PDAC is hypo-enhancement, to which iso-enhancement and very fast/fast washout mode were added in our research. • Using hypo-enhancement/iso-enhancement with very fast/fast washout patterns as the diagnostic criteria for PDAC for solid pancreatic masses on CEUS has high diagnostic accuracy. • The blood supply pattern of PDAC can provide important information, and CEUS has unique advantages in this respect due to its real-time dynamic attenuation ability.
引用
- Jia, Gui, Chen, et al. Evaluation of the diagnostic performance of the EFSUMB CEUS Pancreatic Applications guidelines (2017 version): a retrospective single-center analysis of 455 solid pancreatic masses. Eur Radiol. 2022. PMID: 35699767. doi:10.1007/s00330-022-08879-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。